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ABSTRACT
Objective: The current work is concerned with the synthesis of a series of 4-hydroxy-3-(1-hydroxy-2-(substituted amino)ethyl)-1-phenyl/
methylquinolin-2(1H)-one[III-a(1-5)/III-b(1-5)] and evaluation of its in vitro anticancer activity.
Methods: The starting material for linomide analogs was synthesized by following literature procedures. The carbonyl group was reduced to 
hydroxyl group using sodium borohydride, and the methyl group was brominated using bromine in acetic acid. Further bromine was nucleophilically 
substituted by primary amines. All the synthesized compounds were satisfactorily characterized by infrared, nuclear magnetic resonance, and mass 
spectral data. The synthesized compounds were tested for in vitro anticancer activity against MDA-MB cell line using the MTT assay method.
Results: Among all the synthesized compounds, compound [III-a1;R=C6H5,R1=n-propylamine], [III-b1;R=CH3,R1=n-propylamine], and [III-
b2;R=CH3,R1=methylamine] were found to be most cytotoxic with IC50 value=25 µg against the MDA-MB cell line.
Conclusion: The results of screening studies concluded that compounds with (C6H5 at C1) and (long chain aliphatic and cyclic amines at C3) position 
of quinolin-2-one ring showed moderate activity.
Keywords: Anticancer activity, Human mammary gland, Linomide.
INTRODUCTION
Cancer is characterized by uncontrolled growth of cells. It is a life-
threatening disease affecting the people of all ages and is responsible 
for increase in the mortality rate globally. Inspite of availability of a 
large number of existing anticancer drugs, the development of new 
chemotherapeutics have always been one of the most noteworthy 
challenges due to non-selectivity and emergence of resistance by 
cancerous cells toward existing anticancer compounds [1-3]. Linomide 
is a nitrogen containing pharmacophore identified as a lead molecule for 
anti-human immunodeficiency virus, anticancer, and anti-inflammatory 
agents by many researchers [4]. This leads various research workers 
to make an effort to synthesize linomide analogs with higher potency 
and fewer side effects. Quinoline and its derivatives are important in 
medicinal chemistry because of their wide occurrence in plants and 
drugs and have been reported to have wide biological activity including 
anticancer [5]. Linomide, an immune stimulant quinolone derivative 
increases natural killer cells activity and macrophage cytotoxicity. 
Linomide has been reported to be effective against MH-134 tumor cells 
and prostate cancer [6-8]. It also inhibits angiogenesis and reduces the 
secretion of tumor necrosis factor alpha. In the present investigation, 
we thought of modifying linomide structure on ring nitrogen, carbonyl 
group of acetyl, and replacing phenyl ring by heterocyclic ring system. 
Some of the compounds have shown encouraging anticancer activity 
against MDA-MB cell lines.
METHODS
All the chemicals used were of analytical grade obtained from 
Sprague-Dawley, Fine and Spectrochem. Melting points of synthesized 
compounds were determined by thiel’s melting point apparatus and 
are uncorrected. Fourier Transform infrared spectra were recorded 
on Shimadzu IRAffinity-1 spectrophotometer using KBr pellets. The 
1H nuclear magnetic resonance (1H NMR) and 13C NMR were recorded 
on BrukerAvance II 400 NMR spectrometer using CDCl3 or DMSO-d6 
as solvent and tetramethylsilane as internal standard; chemical shifts 
are expressed as δ values (ppm). The mass spectra were recorded on 
Waters, Q-TOF Micromass (liquid chromatography-mass spectrometry). 
The starting material for the synthesis of title compounds, as shown in 
Scheme 1, was synthesized following literature [9].
Synthesis of (±)4-hydroxy-3-(1-hydroxyethyl)-1-phenyl/methyl 
quinolin-2(1H)-one{I-a/I-b}
A solution of 4-hydroxy-6-methyl/phenylquinolin-2(1H)-one (0.05 M) 
in 10 ml of absolute ethanol was placed in ice water bath, and then a 
solution of sodium borohydride (0.01 M) in 10 ml of cold water was 
added dropwise over a period of 1 hr. The mixture was then allowed to 
stand at room temperature for 10 minutes. 1 ml of dilute hydrochloric 
acid was added to destroy any residual borohydride and then 
transferred to separating funnel. 20 ml of ether was added, swirled, and 
the ether layer was separated, ether was removed under vaccum using 




A solution of I-a/I-b (0.01 M) in acetic acid (8 ml) was cooled to below 
20°C by immersion in ice bath, then bromine (1.6 g, 0.01 M) in acetic 
acid (3 ml) was added dropwise with vigorous stirring over a period of 
1 hr. After completion of addition of bromine, the mixture was stirred 
for 1 hr at room temperature and then diluted with 2.5 ml of water. 
The mixture was neutralized by the addition of 3 ml of 40% sodium 
hydroxide solution. The precipitate obtained was filtered, washed with 
water and dried.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Synthesis of (±)4-hydroxy-3-(1-hydroxy-2-(substituted amino)
ethyl)-1-phenyl/methyl-quinolin-2(1H)-one{III-a(1-5)/III-b(1-5)}
A mixture of II-a/II-b (0.05 M) and substituted primary amines 
(0.05 M) in 20 ml of absolute ethanol was heated under reflux for 
12-16 hrs. After completion of the reaction, the excess solvent was 
distilled off under reduced pressure using rotoevaporator. The 
product was poured into crushed ice, filtered, washed thoroughly 
with water, and recrystallized using suitable solvent. The purity of 
all the newly synthesized compounds was ascertained by thin-layer 
chromatography using (n-hexane:ethyl acetate) in the ratio 7:3 as the 
mobile phase, silica gel G as stationary phase and iodine vapors as 
visualizing agent.
The structural data for the synthesized compounds are given in Table 1.
Anticancer activity
MTT assay method [10]
The human mammary gland (MDA-MB) cell line was obtained from 
the National Centre for Cell Sciences, Pune, India. The cell lines were 
maintained in 96 wells of microtiter plate containing minimum essential 
medium (MEM) media supplemented with 10% heat-inactivated fetal 
calf serum, containing 5% of mixture of gentamicin (10 µg), penicillin 
(100 units/ml), and streptomycin (100 µg/ml) in presence of 5% CO2 at 
37°C for 48-72 hrs. The supernatant from the plate was removed, and 
fresh MEM solution was added and treated with different concentration 
of test compound appropriately diluted with dimethyl sulfoxide 
(DMSO). Control group contained only DMSO. After 48 hrs of incubation 
at 37°C in a humidified atmosphere with 5% CO2, the medium was 
replaced with MTT solution (20 µl, 5 mg per ml in sterile phosphate 
buffered saline) for further 4 hrs incubation. The supernatant was 
carefully aspirated, and the precipitated crystals of “Formazan blue” 
were solubilized by adding DMSO (100 µl). In vitro growth inhibition 
effect of test compound was assessed by determination of conversion 
of MTT into “Formazan blue” by living cells. Optical density (OD) of the 
sample was measured at 492 nm. The results represent the mean of 
five readings (Table 2). The percent cell lysis was calculated using the 
following formula:
Surviving cells (%) = 
Mean OD of  test compound
Mean OD at control
×100
RESULTS
Characterization of the synthesized compounds
(±)4-Hydroxy-3-(1-hydroxyethyl)-1-phenylquinolin-2(1H)-one 
(I-a)
Yield: 70.76%, m.p: 167°C, IR (KBr, cm−1): 3213.41 (-OH); 3064.89, 
3032.10 (aromatic -C-H); 2922.16 (aliphatic-C-H str.); 1646.42 (-C=O 
amide), 1H NMR (DMSO-d6, δ ppm): 17.15 (s, 1H, -OH); 8.2-6.4 (m, 9H, 
Ar-H); 3.93 (t, 1H, -CHOH); 3.36 (s, 1H, -OH of CHOH); 2.6 (s, 3H, -CH3).
(±)4-Hydroxy-3-(1-hydroxyethyl)-1-methylquinolin-2(1H)-one 
(I-b)
Yield: 73.69%, m.p: 70°C, IR (KBr, cm−1): 3392.79.76 (-OH); 3099.61 
(aromatic -C-H); 2976.16, 2931.80 (aliphatic -C-H str.); 1652.01 (-C=O 
amide), 1H NMR (CDCl3, δ ppm): 16.79 (s, 1H, -OH); 8.1-7.0 (m, 4H, Ar-
H); 3.75 (t, 1H, -CHOH); 3.72 (s, 3H, -N-CH3); 3.5 (s, 1H, -OH of CHOH); 
2.7 (s, 3H,-CH3).
Scheme 1: Synthesis of 4-hydroxy-3-(1-hydroxy-2-(substitutedamine)ethyl)-1-phenyl/methylquinolin-2(1H)-one
Table 1: Structural data of the newly synthesized 
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(±)3-(2-Bromo-1-hydroxyethyl)-4-hydroxy-1-phenylquinolin-
2(1H)-one (II-a)
Yield: 75.76%, m.p: 150ºC, IR (KBr, cm−1): 3554.81 (-OH); 3099.61, 
3074.53 (aromatic CH); 1654.92 (-C=O amide); 704.02 (-CH2Br), 1H 
NMR (DMSO-d6, δ ppm): 17.15 (s, 1H, -OH); 8.2-6.4 (m, 9H, Ar-H); 3.93 
(t, 1H, -CHOH); 3.36 (s, 1H, -OH of CHOH); 3.09 (s, 2H, -CH2 of CH2Br).
(±)3-(2-Bromo-1-hydroxyethyl)-4-hydroxy-1-methylquinolin-
2(1H)-one (II-b)
Yield: 79.69%, m.p: 111°C, IR (KBr, cm−1): 3523 (-OH);3074.53 
(aromatic -C-H); 3016.67 (aliphatic -C-H str.); 1637.65 (-C=O amide); 
756.10 (-CH2Br), 1H NMR (CDCl3, δ ppm): 16.79 (s, 1H, -OH); 8.1-7.0 (m, 
4H, Ar-H); 3.75 (t, 1H, -CHOH); 3.72 (s, 3H, -N-CH3); 3.5 (s, 1H, -OH of 
CHOH); 3.05 (s, 2H,-CH2 of CH2Br).
(±)4-Hydroxy-3-(1-hydroxy-2-(propylamino)ethyl)-1-phenyl-
quinolin-2(1H)-one (III-a1)
Yield: 77.45%, m.p: 140ºC, IR (KBr, cm−1):3408.22 (-OH); 3204.89 
(-NH);3096.09, 3062.96 (aromatic -C-H); 2962.66, 2908.96 (aliphatic -C-H 
str.); 1614.42 (-C=O amide),1H NMR (CDCl3, δ ppm): 8.26 (s, 1H, -OH); 8.1-
7.2 (m, 9H, Ar-H); 3.38 (s, 1H, -OH of CHOH); 3.34 (t, 1H, -CHOH); 2.16 
(d, 2H, -CH2); 1.76 (s, 1H, -NH); 1.47 (t, 2H, -CH2 of -CH2CH2-); 1.40 (sext, 
2H, -CH2 of CH2CH3); 0.95 (t, 3H, -CH3), (m/z) = 339.11 [M+1].
(±)4-Hydroxy-3-(1-hydroxy-2-(methylamino)ethyl)-1-phenyl-
quinolin-2(1H)-one (III-a2)
Yield: 80.12%, m.p: 133°C, IR (KBr, cm−1):3446.79 (-OH); 3202.43 
(-NH);3076.61, 3064.89 (aromatic -C-H); 2962.24 (aliphatic -C-H str.); 
1631.78 (-C=O amide), 1H NMR (CDCl3, δ ppm): 8.15 (s, 1H, -OH); 8.1-
Table 2: In vitro anticancer activity of 4-hydroxy-3-(1-hydroxy-2-(substituedamine) 
ethyl)-1-phenyl/methylquinolin-2 (1H)-onederivatives
S. No. Compound Concentration (µG) OD at 492 nm % of cell lysis as observed IC50
1 III-a1 10 0.495 No lysis 25 µg
20 0.469 No lysis
25 0.300 50 lysis
30 0.295 50 lysis
50 0.289 100 lysis
2 III-a2 10 0.488 No lysis
20 0.424 No lysis
25 0.420 No lysis
30 0.413 No lysis
50 0.384 No lysis
3 III-a3 10 0.549 No lysis
20 0.511 No lysis
25 0.500 No lysis
30 0.461 No lysis
50 0.386 No lysis
4 III-a4 10 0.614 No lysis 30-50 µg
20 0.531 No lysis
25 0.520 No lysis
30 0.514 No lysis
50 0.300 100 lysis
5 III-a5 10 0.687 No lysis 30-50 µg
20 0.672 No lysis
25 0.595 No lysis
30 0.587 No lysis
50 0.396 100 lysis
6 III-b1 10 0.687 No lysis 25 µg
20 0.645 N0 lysis
25 0.295 50 lysis
30 0.290 100 lysis
50 0.285 100 lysis
7 III-b2 10 0.783 No lysis 25 µg
20 0.719 No lysis
25 0.310 50 lysis
30 0.300 50 lysis
50 0.295 100 lysis
8 III-b3 10 0.628 No lysis
20 0.615 No lysis
25 0.578 No lysis
30 0.572 No lysis
50 0.557 No lysis
9 III-b4 10 0.535 No lysis
20 0.520 No lysis
25 0.490 No lysis
30 0.490 No lysis
50 0.458 No lysis
10 III-b5 10 0.675 No lysis
20 0.567 No lysis
25 0.511 No lysis
30 0.507 No lysis
50 0.456 No lysis
11 Vincristine (standard) 30 1.153 90
OD: Optical density
228
Asian J Pharm Clin Res, Vol 10, Issue 8, 2017, 225-228
 Bajaj et al. 
6.5 (m, 9H, Ar-H); 4.04 (t, 1H, -CHOH); 3.25(s, 1H, -OHof CHOH); 3.22 (s, 
3H, -CH3); 2.17 (d, 2H, -CH2); 2.05 (s, 1H, -NH).
(±)3-(2-(Cyclopropylamino)-1-hydroxyethyl)-4-hydroxy-1-
phenyl-quinolin-2(1H)-one (III-a4)
Yield: 72.56%, m.p: 135°C, IR (KBr, cm−1): 3474.81 (-OH); 3244.27 
(-NH); 3064.89, 3024.82 (aromatic -C-H); 2924.09 (aliphatic -C-H str.); 
1643.35 (-C=O amide), 1H NMR (CDCl3, δ ppm): 8.14 (s, 1H, -OH); 7.9-
6.5 (m, 9H, Ar-H); 3.38 (t, 1H, -CHOH); 3.37 (s, 1H, -OHof CHOH); 2.16 
(d, 2H, -CH2); 1.8(s, 1H, -NH); 1.34 (pent, 1H, -CH of cyclopropylamine); 
1.32 (d, 4H, 2,3-CH2 of cyclopropylamine).
(±)4-Hydroxy-3-(1-hydroxy-2-(propylamino)ethyl)-1-methyl-
quinolin-2(1H)-one (III-b1)
Yield: 74.94%, m.p: 135°C, IR (KBr, cm−1):3417.86 (-OH); 3254.27 
(-NH);3044.27 (aromatic -C-H); 2999.16, 2929.87 (aliphatic -C-H str.); 
1656.16 (-C=O amide), 1H NMR (CDCl3, δ ppm): 8.18 (s, 1H, -OH); 8.1-7.1 
(m, 4H, Ar-H); 3.77 (t, 1H, -CHOH); 3.72 (s, 3H, -N-CH3); 3.3 (s, 1H, -OH of 
CHOH); 2.16 (d, 2H, -CH2); 1.75 (s, 1H, -NH); 1.47 (t, 2H, -CH2 of -CH2CH2-); 
1.39 (sext, 2H, -CH2 of CH2CH3); 0.90 (t, 3H, -CH3), (m/z) = 276.12 [M+1].
(±)4-Hydroxy-3-(1-hydroxy-2-(methylamino)ethyl)-1-methyl-
quinolin-2(1H)-one (III-b2)
Yield: 81.98%, m.p: 130°C,IR (KBr, cm−1):3421.72 (-OH); 3217.27 
(-NH);3067.27 (aromatic -C-H); 2976.16, 2931.72 (aliphatic -C-H str.); 
1635.64 (-C=O amide), 1H NMR (CDCl3, δ ppm): 8.11 (s, 1H, -OH); 7.9-6.9 
(m, 4H, Ar-H); 3.78 (t, 1H, -CHOH); 3.73 (s, 3H, -N-CH3) 3.36 (s, 1H, -OH 
of CHOH); 3.33 (s, 3H, -CH3); 2.17 (d, 2H, -CH2); 2.03 (s, 1H, -NH).
DISCUSSION
As mentioned in the scheme, we have synthesized two series of 
quinolin-2-one derivatives which include (±)4-hydroxy-3-(1-hydroxy-
2-(substituted amino)ethyl)-1-phenyl-quinolin-2(1H)-one (III-a 
series) and(±)4-hydroxy-3-(1-hydroxy-2-(substituted amino)ethyl)-1-
methyl-quinolin-2(1H)-one (III-b series). The acetyl group compound 
Ia\Ib was reduced by NaBH4 to the corresponding chiral alcohol and 
halogenation with bromine in acetic acid gave β-haloalcohol. In the 
final step, halogen was substituted by primary amine nucleophiles. 
MTT assay is a colorimetric assay that measures the reduction of 
yellow 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) by mitochondrial succinate dehydrogenase. Since the reduction 
of MTT can only occur in metabolically active cells the level of activity is 
a measure of the viability of the cells.
CONCLUSION
A series of (±)4-hydroxy-3-(1-hydroxy-2-(substituted amino)ethyl)-1-
phenyl/methylquinolin-2(1H)-one derivatives were synthesized and 
evaluated for their anticancer activity by MTT assay method. From the 
obtained result, it was concluded that, among all, compound (III-a1), 
(III-b1), and (III-b2) were found to be most potent with IC50 value=25 µg 
whereas compound (III-a4) and (III- a5) showed moderate activity with 
IC50 value=30-50 µg and were therefore found to be active against the 
in vitro anticancer activity. The results of screening studies suggested 
that compounds with C6H5 at C1 and long chain aliphatic and cyclic 
amines at C3 position of quinolin-2-one ring showed moderate activity.
Thus, research work was undertaken for substitution at 3rd position of 
quinolin-2-one ring. The encouraging results shown may lead to the 
development of novel anticancer drugs, if explored further.
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